Cat. No.: HY-111407

MK-8353

(Synonyms: SCH900353)

5 Cited Publications

Customer Review

Based on 5 publication(s) in Google Scholar

MK-8353 (SCH900353) is a potent, selective and orally available ERK1/2 inhibitor, with IC₅₀s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.

For research use only. We do not sell to patients.

Purity: 98.13%
CAS No.: 1184173-73-6
Formula: C₃₇H₄₁N₉O₃S
Molecular Weight:691.84

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

MK-8353 Chemical Structure

CAS No.: 1184173-73-6

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

MK-8353 (SCH900353) is a potent, selective and orally available ERK1/2 inhibitor, with IC₅₀s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.

IC₅₀ & Target^[1]

ERK2

8.8 nM (IC₅₀)

ERK1

23 nM (IC₅₀)

All ERK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A2058	IC₅₀	371 nM Compound: 20; MK-8353	Antiproliferative activity against human A2058 cells harboring BRAF V600E/D mutant measured after 4 days Antiproliferative activity against human A2058 cells harboring BRAF V600E/D mutant measured after 4 days	[PMID: 30034615]
COLO 205	IC₅₀	23 nM Compound: 20; MK-8353	Antiproliferative activity against human COLO205 cells harboring BRAF V600E/D mutant measured after 4 days Antiproliferative activity against human COLO205 cells harboring BRAF V600E/D mutant measured after 4 days	[PMID: 30034615]
HT-29	IC₅₀	51 nM Compound: 20; MK-8353	Antiproliferative activity against human HT-29 cells harboring BRAF V600E/D mutant measured after 4 days Antiproliferative activity against human HT-29 cells harboring BRAF V600E/D mutant measured after 4 days	[PMID: 30034615]

In Vitro

MK-8353 is a potent, selective and orally available ERK1/2 inhibitor, with IC₅₀s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity. MK-8353 only at 1 μM shows >50% inhibition on 3 kinases (CLK2, FLT4, and Aurora B), and no other kinases tested are inhibited by >35% at 0.1 μM. MK-8353 also shows potent antitumor activity against various cancer cell lines, such Malme-3M cells (Melanoma), Colo-205 cells (Colon), NCI-H292 cells (Lung), A-549 cells (NSCLC), 8505C cells (Thyroid), SW-626 cells (Ovarian), with EC₅₀s of 21 nM, 19 nM, 130 nM, 230 nM, 210 nM, 108 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

MK-8353 (60 mg/kg, p.o., bid (twice daily)) causes at least 50% tumor growth inhibition or regression in 83% of the animal models bearing different tumor cells, including LOX, Colo-205, MIA PaCa-2, and Calu-6 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1184173-73-6
Appearance Solid
Molecular Weight 691.84
Formula C₃₇H₄₁N₉O₃S
Color White to light yellow
SMILES

O=C([C@@]1(SC)CN(CC(N2CC=C(C3=CC=C(C4=NN(C)C=N4)C=C3)CC2)=O)CC1)NC5=CC6=C(NN=C6C7=CC=C(OC(C)C)N=C7)C=C5
Synonyms

SCH900353
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (5)

All WB

Sort by:

Journal Impact Factor

Nat Nanotechnol

Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. [Abstract]

2021 Jul;16(7):830-839. PMID: 33958764
J Nanobiotechnology

Delivery of an ERK inhibitor using bioactive lipid nanoparticles reduces angiogenesis and prevents oral squamous cell carcinoma development. [Abstract]

2025 Jul 18;23(1):524. PMID: 40682120
Cell Rep

Biased signaling by mutant EGFR underlies dependence on PKCα in lung adenocarcinoma. [Abstract]

2024 Dec 3;43(12):115026. PMID: 39630579
Mol Med Rep

S100A1 expression is increased in spinal cord injury and promotes inflammation, oxidative stress and apoptosis of PC12 cells induced by LPS via ERK signaling. [Abstract]

2023 Feb;27(2):30. PMID: 36524376

MK-8353 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Feb;27(2):30. [Abstract]

MK‑8353 partially counteractes the inhibitory effects of S100A1 overexpression on Nrf2 level in PC12 cells.
State University of New York at Stony Brook

2025.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (144.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4454 mL

7.2271 mL

14.4542 mL

5 mM

0.2891 mL

1.4454 mL

2.8908 mL

10 mM

0.1445 mL

0.7227 mL

1.4454 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Moschos SJ, et al. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018 Feb 22;3(4). pii: 92352. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4454 mL	7.2271 mL	14.4542 mL	36.1355 mL
	5 mM	0.2891 mL	1.4454 mL	2.8908 mL	7.2271 mL
	10 mM	0.1445 mL	0.7227 mL	1.4454 mL	3.6136 mL
	15 mM	0.0964 mL	0.4818 mL	0.9636 mL	2.4090 mL
	20 mM	0.0723 mL	0.3614 mL	0.7227 mL	1.8068 mL
	25 mM	0.0578 mL	0.2891 mL	0.5782 mL	1.4454 mL
	30 mM	0.0482 mL	0.2409 mL	0.4818 mL	1.2045 mL
	40 mM	0.0361 mL	0.1807 mL	0.3614 mL	0.9034 mL
	50 mM	0.0289 mL	0.1445 mL	0.2891 mL	0.7227 mL
	60 mM	0.0241 mL	0.1205 mL	0.2409 mL	0.6023 mL
	80 mM	0.0181 mL	0.0903 mL	0.1807 mL	0.4517 mL
	100 mM	0.0145 mL	0.0723 mL	0.1445 mL	0.3614 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

MK-8353

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) MK-8353

All ERK Isoforms

Biological Activity

Chemical Information

Publications (5)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MK-8353 Related Classifications

Cat. No.: HY-111407